CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 21 of 21 entries

View as:

Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation

Phase: N/A Priority: Normal

NCT ID: NCT01574716 Org: User:

Start: 08/07/12 End: 08/02/16 Due: 08/02/17

Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00428766 Org: User:

Start: 06/30/05 End: 12/31/07 Due: 12/31/08

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Phase: N/A Priority: Normal

NCT ID: NCT01507545 Org: User:

Start: 03/27/12 End: 10/20/13 Due: 10/20/14

Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects

Phase: N/A Priority: Normal

NCT ID: NCT01357759 Org: User:

Start: 05/31/13 End: 07/31/14 Due: 07/31/15

Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)

Phase: N/A Priority: Normal

NCT ID: NCT02357147 Org: User:

Start: 11/03/15 End: 11/30/18 Due: 11/30/19

A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00325494 Org: User:

Start: 05/31/06 End: 09/30/08 Due: 09/30/09

A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung

Phase: N/A Priority: Normal

NCT ID: NCT01218516 Org: User:

Start: 06/27/11 End: 11/01/13 Due: 11/01/14

An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00570713 Org: User:

Start: 12/31/07 End: 12/31/09 Due: 12/31/10

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Phase: N/A Priority: Normal

NCT ID: NCT00849667 Org: User:

Start: 04/16/09 End: 04/12/13 Due: 04/12/14

Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy

Phase: N/A Priority: Normal

NCT ID: NCT00318370 Org: User:

Start: 05/31/06 End: 06/30/10 Due: 06/30/11

A Study of of MORAb-004 in Subjects With Solid Tumors

Phase: N/A Priority: Normal

NCT ID: NCT00847054 Org: User:

Start: 03/31/09 End: 04/30/14 Due: 04/30/15

Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma

Phase: N/A Priority: Normal

NCT ID: NCT01123304 Org: User:

Start: 05/31/10 End: 03/31/12 Due: 03/31/13

An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma

Phase: N/A Priority: Normal

NCT ID: NCT00738582 Org: User:

Start: 12/31/08 End: 01/10/14 Due: 01/10/15

Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas

Phase: N/A Priority: Normal

NCT ID: NCT01203618 Org: User:

Start: 02/28/11 End: 08/31/13 Due: 08/31/14

An Open Label Extension Study of the Efficacy of MORAb-003

Phase: N/A Priority: Normal

NCT ID: NCT01018563 Org: User:

Start: 01/13/10 End: 03/05/13 Due: 03/05/14

A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

Phase: N/A Priority: Normal

NCT ID: NCT01521325 Org: User:

Start: 09/30/11 End: 03/31/13 Due: 03/31/14

An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00738699 Org: User:

Start: 09/30/08 End: 01/31/12 Due: 01/31/13

Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer

Phase: N/A Priority: Normal

NCT ID: NCT01004380 Org: User:

Start: 11/30/09 End: 10/31/12 Due: 10/31/13

Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC

Phase: N/A Priority: Normal

NCT ID: NCT01761240 Org: User:

Start: 06/19/13 End: 02/09/16 Due: 02/09/17

A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma

Phase: N/A Priority: Normal

NCT ID: NCT01212276 Org: User:

Start: 12/31/10 End: 09/30/12 Due: 09/30/13

MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Phase: N/A Priority: Normal

NCT ID: NCT01748721 Org: User:

Start: 11/30/13 End: 05/31/15 Due: 05/31/16

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation	NCT01574716	Morphotek	user2@example.com	None	2012-08-07	2016-08-02	2017-08-02	-	-	2025-07-14
Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer	NCT00428766	Morphotek	user2@example.com	None	2005-06-30	2007-12-31	2008-12-31	-	-	2025-07-14
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)	NCT01507545	Morphotek	user2@example.com	None	2012-03-27	2013-10-20	2014-10-20	-	-	2025-07-14
Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects	NCT01357759	Morphotek	user2@example.com	None	2013-05-31	2014-07-31	2015-07-31	-	-	2025-07-14
Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)	NCT02357147	Morphotek	user2@example.com	None	2015-11-03	2018-11-30	2019-11-30	-	-	2025-07-14
A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer	NCT00325494	Morphotek	user2@example.com	None	2006-05-31	2008-09-30	2009-09-30	-	-	2025-07-14
A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung	NCT01218516	Morphotek	user2@example.com	None	2011-06-27	2013-11-01	2014-11-01	-	-	2025-07-14
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer	NCT00570713	Morphotek	user2@example.com	None	2007-12-31	2009-12-31	2010-12-31	-	-	2025-07-14
Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse	NCT00849667	Morphotek	user2@example.com	None	2009-04-16	2013-04-12	2014-04-12	-	-	2025-07-14
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy	NCT00318370	Morphotek	user2@example.com	None	2006-05-31	2010-06-30	2011-06-30	-	-	2025-07-14
A Study of of MORAb-004 in Subjects With Solid Tumors	NCT00847054	Morphotek	user2@example.com	None	2009-03-31	2014-04-30	2015-04-30	-	-	2025-07-14
Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma	NCT01123304	Morphotek	user2@example.com	None	2010-05-31	2012-03-31	2013-03-31	-	-	2025-07-14
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma	NCT00738582	Morphotek	user2@example.com	None	2008-12-31	2014-01-10	2015-01-10	-	-	2025-07-14
Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas	NCT01203618	Morphotek	user2@example.com	None	2011-02-28	2013-08-31	2014-08-31	-	-	2025-07-14
An Open Label Extension Study of the Efficacy of MORAb-003	NCT01018563	Morphotek	user2@example.com	None	2010-01-13	2013-03-05	2014-03-05	-	-	2025-07-14
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers	NCT01521325	Morphotek	user2@example.com	None	2011-09-30	2013-03-31	2014-03-31	-	-	2025-07-14
An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer	NCT00738699	Morphotek	user2@example.com	None	2008-09-30	2012-01-31	2013-01-31	-	-	2025-07-14
Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer	NCT01004380	Morphotek	user2@example.com	None	2009-11-30	2012-10-31	2013-10-31	-	-	2025-07-14
Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC	NCT01761240	Morphotek	user2@example.com	None	2013-06-19	2016-02-09	2017-02-09	-	-	2025-07-14
A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma	NCT01212276	Morphotek	user2@example.com	None	2010-12-31	2012-09-30	2013-09-30	-	-	2025-07-14
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma	NCT01748721	Morphotek	user2@example.com	None	2013-11-30	2015-05-31	2016-05-31	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance